Overview

G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT

Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Allo-HSCT is the most effective way to cure high-risk MDS patients. At present, the best conditioning regimen for high-risk MDS patients undergoing allo-HSCT remains in discussion. In this prospective study, the safety and efficacy of G-CSF+DAC+BUCY and G-CSF+DAC+BF conditioning regimens in high-risk MDS patients undergoing allo-HSCT are evaluated.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Nanfang Hospital of Southern Medical University
Collaborators:
First People's Hospital of Chenzhou
Guangzhou First People's Hospital
Institute of Hematology and Blood Diseases Hospital
Peking University People's Hospital
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
The Seventh Affiliated Hospital of Sun Yat-sen University
Treatments:
Busulfan
Cyclophosphamide
Decitabine
Fludarabine
Lenograstim